Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells

Oncogene

Volumn 30, Issue 5, 2011, Pages 619-630

  Takayama, K ^a,b   Tsutsumi, S ^c   Katayama, S ^d   Okayama, T ^e   Horie Inoue, K ^b   Ikeda, K ^b   Urano, T ^a,b   Kawazu, C ^d   Hasegawa, A ^d   Ikeo, K ^e   Gojyobori, T ^e   Ouchi, Y ^a   Hayashizaki, Y ^d   Aburatani, H ^c   Inoue, S ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d RIKEN YOKOHAMA INSTITUTE   (Japan)

^e NATIONAL INSTITUTE OF GENETICS   (Japan)

Author keywords

androgen receptor; CAGE; Chip chip; prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; HISTONE H3; MICRORNA;

ARTICLE; BINDING SITE; CANCER CELL; CAP ANALYSIS OF GENE EXPRESSION; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME 21; CONTROLLED STUDY; DNA MICROARRAY; GENE CLUSTER; GENE EXPRESSION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC CODE; GENETIC REGULATION; HUMAN; HUMAN CELL; HUMAN GENOME; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE;

ACETYLATION; ANDROGENS; BINDING SITES; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DIHYDROTESTOSTERONE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; GENOMICS; HISTONES; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE;

EID: 79551646237     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.436     Document Type: Article

References (46)

1. Attard G, Clark J, Ambroisine L, Mills IG, Fisher G, Flohr P et al. (2008). Heterogeneity and clinical significance of ETV1 transloca-tions in human prostate cancer. Br J Cancer 99: 314-320.
2. Balint I, Muller A, Nagy A, Kovacs G. (2004). Cloning and characterisation of the RBCC728/TRIM36 zinc-binding protein from the tumor suppressor gene region at chromosome 5q22.3. Gene 332: 45-50.
3. Bernstein BE, Kamal M, Lindblad-Toh K, Bekiranov S, Bailey DK, Huebert DJ et al. (2005). Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 120: 169-181.
4. Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N et al. (2005). The transcriptional landscape of the mammalian genome. Science 309: 1559-1563.
5. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R et al. (2004). Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39.
6. de Hoon MJ, Imoto S, Nolan J, Miyano S. (2004). Open source clustering software. Bioinformatics 20: 1453-1454.
7. Debes JD, Tindall DJ. (2004). Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351: 1488-1490.
8. Dehm SM, Tindall DJ. (2006). Molecular regulation of androgen action in prostate cancer. J Cell Biochem 99: 333-344.
9. Dennis Jr G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC et al. (2003). DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 4: R3.
10. Eisen MB, Spellman PT, Brown PO, Botstein D. (1998). Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868.
11. FANTOM Consortium (2009). The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. Nat Genet 41: 553-562.
12. Hermans KG, van der Korput HA, van Marion R, van de Wijngaart DJ, Ziel-van der Made A, Dits NF et al. (2008). Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res 68: 7541-7549.
13. Ho LL, Kench JG, Handelsman DJ, Scheffer GL, Stricker PD, Grygiel JG et al. (2008). Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer. Prostate 68: 1421-1429.
14. Horie-Inoue K, Takayama K, Bono HU, Ouchi Y, Okazaki Y, Inoue S. (2006). Identification of novel steroid target genes through the combination of bioinformatics and functional analysis of hormone response elements. Biochem Biophys Res Commun 339: 99-106.
15. Huang DW, Sherman BT, Lempicki RA. (2009). Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nat Protoc 4: 44-57.
16. Katayama S, Tomaru Y, Kasukawa T, Waki K, Nakanishi M, Nakamura M et al. (2005). Antisense transcription in the mammalian transcriptome. Science 309: 1564-1566.
17. 0-leading label of capped transcripts. Genome Biol 8: R42.
18. Kim TH, Barrera LO, Zheng M, Qu C, Singer MA, Richmond TA et al. (2005). A high-resolution map of active promoters in the human genome. Nature 436: 876-880. (Pubitemid 41160649)
19. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K et al. (2004). Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101: 811-816.
20. Leite KR, Sousa-Canavez JM, Reis ST, Tomiyama AH, Camara-Lopes LH, Sanudo A et al. (2009). Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. Urol Oncol (e-pub ahead of print).
21. Liu P, Ramachandran S, Ali Seyed M, Scharer CD, Laycock N, Dalton WB et al. (2006). Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 66: 4011-4019.
22. Louro R, Nakaya HI, Amaral PP, Festa F, Sogayar MC, da Silva AM et al. (2007). Androgen responsive intronic non-coding RNAs. BMC Biol 5: 4.
23. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ et al. (2002). Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 62: 2220-2226.
24. Maeda N, Nishiyori H, Nakamura M, Kawazu C, Murata M, Sano H et al. (2008). Development of a DNA barcode tagging method for monitoring dynamic changes in gene expression by using an ultra high-throughput sequencer. Biotechniques 45: 95-97.
25. Massie CE, Adryan B, Barbosa-Morais NL, Lynch AG, Tran MG, Neal DE et al. (2007). New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 8: 871-878.
26. Pandini G, Genua M, Frasca F, Vigneri R, Belfiore A. (2009). Sex steroids upregulate the IGF-1R in prostate cancer cells through a nongenotropic pathway. Ann NY Acad Sci 1155: 263-267.
27. Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, Svensson MA et al. (2009). N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 11: 804-811.
28. Prescott JL, Blok L, Tindall DJ. (1998). Isolation and androgen regulation of the human homeobox cDNA, NKX3.1. Prostate 35: 71-80.
29. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH et al. (2009). miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 69: 7165-7169.
30. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL et al. (2004). JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 64: 6854-6857.
31. Shang Y, Myers M, Brown M. (2002). Formation of the androgen receptor transcription complex. Mol Cell 9: 601-610.
32. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M et al. (2007). An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci USA 104: 19983-19988.
33. Shiraki T, Kondo S, Katayama S, Waki K, Kasukawa T, Kawaji H et al. (2003). Cap analysis gene expression for high-throughput analysis of transcriptional starting point and identification of promoter usage. Proc Natl Acad Sci USA 100: 15776-15781.
34. Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P. (2009). The role of microRNA-221 and microRNA-222 in androgen-indepen-dent prostate cancer cell lines. Cancer Res 69: 3356-3363.
35. Suzuki H, Ueda T, Ichikawa T, Ito H. (2003). Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer 10: 209-216.
36. Takayama K, Horie-Inoue K, Ikeda K, Urano T, Murakami K, Hayashizaki Y et al. (2008). FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells. Biochem Biophys Res Commun 374: 388-393.
37. Takayama K, Kaneshiro K, Tsutsumi S, Horie-Inoue K, Ikeda K, Urano T et al. (2007). Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene 26: 4453-4463.
38. Takayama K, Tsutsumi S, Suzuki T, Horie-Inoue K, Ikeda K, Kaneshiro K et al. (2009). Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth. Cancer Res 69: 137-142.
39. Velasco AM, Gillis KA, Li Y, Brown EL, Sadler TM, Achilleos M et al. (2004). Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology 145: 3913-3924.
40. Wang Q, Carroll JS, Brown M. (2005). Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell 19: 631-642.
41. Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK et al. (2007). A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 27: 380-392.
42. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J et al. (2009). Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138: 245-256.
43. Wilson BJ, Giguere V. (2007). Identification of novel pathway partners of p68 and p72 RNA helicases through Oncomine meta-analysis. BMC Genomics 8: 419.
44. Yochum GS, Cleland R, McWeeney S, Goodman RH. (2007). An antisense transcript induced by Wnt/beta-catenin signaling decreases E2F4. J Biol Chem 282: 871-878.
45. Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X et al. (2010). An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17: 443-454.
46. Yu SY, Chan DW, Liu VW, Ngan HY. (2009). Inhibition of cervical cancer cell growth through activation of upstream kinases of AMP-activated protein kinase. Tumour Biol 30: 80-85.